Drug Companies Join Medical Psychedelic Movement—but Without the High

Filament Health Announces Closing of Warrant Exercise, Note Conversion And Concurrent Private Placement Of Common Shares

Filament Health Announces Authorization Of Phase 2 Clinical Trial For PEX010 In The Treatment of Methamphetamine Use Disorder

Filament Health Announces Warrant Exercise And Note Conversion By Negev Capital And Concurrent Private Placement Of Common Shares To Benjamin Lightburn Chief Executive Officer